Please sign in to follow a disease.
Beta-thalassemia major
MONDO:0016486Beta-thalassemia (BT) major is a severe early-onset form of BT characterized by severe anemia requiring regular red blood cell transfusions.
Also known as: Beta thalassemia Major, Cooley anaemia, Cooley anemia, Cooley's Anaemia, Cooley's Anemia, Mediterranean anaemia, Mediterranean anemia
73 clinical trials for this condition and its sub-types, 49 tagged with Beta-thalassemia major itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
A drug that protects the liver may make stem cell transplants safer for children with sickle cell disease
Cure Recruiting nowThis trial tests whether giving defibrotide before and after a stem cell transplant can prevent a serious liver condition called sinusoidal obstructive syndrome (SOS) in children and young adults with sickle cell disease or beta thalassemia. Participants receive defibrotide start…
Phase 2 • Sponsor: New York Medical College • Aim: Cure
Last updated Jul 29, 2026 00:00 UTC
-
Gene therapy aims to free patients from lifelong blood transfusions
Cure Recruiting nowThis study follows people who have already received an experimental gene therapy called BRL-101 for transfusion-dependent β-thalassemia, a severe blood disorder requiring regular transfusions. Researchers will monitor participants over the long term to check for safety issues, su…
Sponsor: Bioray Laboratories • Aim: Cure
Last updated Jul 23, 2026 00:00 UTC
-
Gene editing could cure sickle cell and thalassemia in new trial
Cure Recruiting nowThis early-stage trial tests a gene-editing treatment for people with severe sickle cell disease or beta-thalassemia. The approach uses the patient's own blood stem cells, which are edited to boost fetal hemoglobin—a healthy type that can replace the defective hemoglobin. Up to 1…
Phase 1 • Sponsor: Daniel Bauer • Aim: Cure
Last updated Jun 27, 2026 09:01 UTC
-
New pill may cut blood transfusions for kids with thalassemia
Disease control Recruiting nowThis study tests a drug called mitapivat in children aged 1 to 17 with alpha- or beta-thalassemia who need regular blood transfusions. The goal is to see if mitapivat can reduce the number of transfusions needed compared to a placebo. The study involves 54 participants and lasts …
Phase 3 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New hope for thalassemia patients: drug may cut blood transfusions
Disease control Recruiting nowThis study is testing a drug called luspatercept in adults with a severe blood disorder called beta-thalassemia who need regular blood transfusions. The goal is to see if the drug can reduce how many transfusions they need and improve their hemoglobin levels. Researchers will fol…
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Mismatched donor stem cell transplant could widen treatment access for sickle cell disease
Disease control Recruiting nowThis study tests a stem cell transplant using cells from mismatched unrelated or partially matched family donors for people with severe sickle cell disease and other transfusion-dependent anemias. The approach removes certain immune cells (T-cells) from the donated stem cells to …
Phase 1/2 • Sponsor: Paul Szabolcs • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Old drugs, new hope: could a thalidomide combo free thalassemia patients from transfusions?
Disease control Recruiting nowThis study tests whether a combination of two drugs, thalidomide and hydroxyurea, can safely boost fetal hemoglobin levels in people with beta thalassemia major. The goal is to improve overall hemoglobin levels and reduce the need for regular blood transfusions. The trial include…
Sponsor: Riphah International University • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Gene therapy aims to free Beta-Thalassemia patients from lifelong transfusions
Disease control Recruiting nowThis study tests a single-dose gene therapy for people with transfusion-dependent beta-thalassemia, a blood disorder that requires regular red blood cell transfusions. The therapy uses a patient's own stem cells, modified with a virus to produce healthy hemoglobin, and then infus…
Phase 2 • Sponsor: Fondazione Telethon • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New stem cell transplant trial aims to treat sickle cell disease and other blood disorders
Disease control Recruiting nowThis phase 2 trial tests a stem cell transplant from a donor for people with high-risk sickle cell disease, thalassemia, and other red blood cell disorders. Participants receive drugs and low-dose radiation before the transplant to help the new cells take hold. The study will tra…
Phase 2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Could a One-Time gene fix free thalassemia patients from lifelong transfusions?
Disease control Recruiting nowThis study tests a new gene therapy for adults with transfusion-dependent beta-thalassemia, a severe blood disorder. Doctors take the patient's own blood stem cells, add a healthy gene to make normal hemoglobin, and return the cells. The goal is to reduce or stop the need for reg…
Phase 1/2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
CRISPR stem cell therapy could end transfusions for sickle cell and thalassemia patients
Disease control Recruiting nowThis study tests a one-time treatment called CTX001, which uses CRISPR gene editing to modify a patient's own stem cells to produce more fetal hemoglobin. The goal is to reduce or eliminate the need for blood transfusions in people with transfusion-dependent beta-thalassemia or s…
Phase 3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New combo aims to cut transfusions for blood disorder patients
Disease control Recruiting nowThis Phase 2 trial tests whether adding low-dose thalidomide to luspatercept can reduce the number of blood transfusions needed by adults with transfusion-dependent β-thalassemia. 78 participants will be randomly assigned to receive either the combination or luspatercept alone fo…
Phase 2 • Sponsor: Rongrong Liu • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New pill aims to clean iron from organs in blood disorder patients
Disease control Recruiting nowThis trial tests an oral drug called SP-420 in about 90 adults with transfusion-dependent β-thalassemia or low-risk myelodysplastic syndromes (MDS). The goal is to see how well SP-420 removes excess iron from the liver and other organs, and whether it is safe. Participants take t…
Phase 2 • Sponsor: Pharmacosmos A/S • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Chemo-Free stem cell transplant could change thalassemia treatment
Disease control Recruiting nowThis early study tests a new type of stem cell transplant called 'super transplant' for children aged 7-12 with severe thalassemia. Unlike standard transplants, this one does not require chemotherapy beforehand and aims to avoid graft-versus-host disease. Only 5 participants will…
Sponsor: Hu Peng • Aim: Disease control
Last updated Jun 26, 2026 13:17 UTC
-
New study aims to uncover the mystery of exercise fatigue in thalassemia patients
Knowledge-focused Recruiting nowThis study looks at why people with transfusion-dependent beta thalassemia have trouble exercising. Researchers will compare 36 patients to healthy volunteers using bike tests, blood samples, and questionnaires. The goal is to find the physical and mental factors that limit their…
Sponsor: Centre Hospitalier Metropole Savoie • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC